Please login to the form below
pomalidomide
This page shows the latest pomalidomide news and features for those working in and with pharma, biotech and healthcare.
Sanofi signs $1bn licence agreement for Eureka’s novel multiple myeloma drug
inhibitor. It was cleared for use in combination with pomalidomide and dexamethasone (pom-dex), a standard regimen for the treatment of myeloma.
Latest news
-
J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
Sarclisa is currently approved in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of relapsed or refractory multiple myeloma who have received at least two prior therapies.
-
Second Sarclisa combination regimen for multiple myeloma approved in EU
In the EU, Sarclisa is already approved for use in combination with pomalidomide and dexamethasone (pom-dex), a standard regimen for the treatment of myeloma, for the treatment of patients with
-
In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa
The CHMP positive opinion is for Sarclisa (isatuximab) as a treatment for patients with relapsed and refractory multiple myeloma in combination with Bristol-Myers Squibb’s Pomalyst (pomalidomide) and dexamethasone – a
-
BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma
Celgene’s Pomalyst/Innovid (pomalidomide) and dexamethasone in relapsed/refractory patients.
-
FDA approves Sanofi’s key cancer drug Sarclisa for myeloma
It has been approved for use in combination with pomalidomide and dexamethasone (pom-dex), a standard regimen for the treatment of myeloma. ... Sarclisa used in combination with pomalidomide and dexamethasone offers an important new treatment option for
More from news
Approximately 6 fully matching, plus 35 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
BMS will become the fourth largest pharma firm by sales – behind Pfizer, Novartis and Roche – and the addition of new Celgene brands like blood cancer therapies Revlimid (lenalidomide) and Pomalyst (pomalidomide)
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Live Webinar: Navigating the Nuances of Europe's MedTech Industry
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Pfizer, Mylan move ahead with generics merger and spin-out
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
